Twelve-dose drug regimen now also an option for preventing tuberculosis in children and adolescents

Affiliations

¹ The Children's Hospital at Westmead, Sydney, Australia2Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.

Editorial

Ben J Marais. JAMA Pediatr. 2015 Mar.

. 2015 Mar;169(3):208-10.

doi: 10.1001/jamapediatrics.2014.3157.

¹ The Children's Hospital at Westmead, Sydney, Australia2Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.

No abstract available

Comment on

Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Villarino ME, et al. JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. JAMA Pediatr. 2015. PMID: 25580725 Free PMC article. Clinical Trial.